Fundraising FoxNextCure
NASDAQ: NXTCBeltsville, US · Founded 2015 · Delaware corporation · 11 known investors
Find your way into NextCure
657 people in our graph share verified history with the NextCure team — schools, employers, funds. One of them is your warm intro.
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
Founders & leadership
NextCure was founded in 2015 by Michael Richman.
Board
Investors · 11
How we know: Canaan Partners's portfolio page · the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements$449.9M disclosed across 4 rounds · 2015–2026
- $320MraisedJul 2026Source ↗
▶$21.5MraisedDec 2025 · 12 investors · BiotechnologyRule 506(b)
- Timothy MayerExecutive Officer
- Michael RichmanExecutive Officer, Director
- Elaine V. JonesDirector
- Udayan GuhaExecutive Officer
- Anne BorgmanDirector
- Steven P. CobournExecutive Officer
- David KabakoffDirector
- Sourav KunduExecutive Officer
- Ellen FeigalDirector
- Stephen WebsterDirector
- John G. HoustonDirector
- Kevin ShawExecutive Officer
- Offering amount
- $21.5M
- Amount sold
- $21.5M
- Finders' fees
- $1.2M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$93.4MraisedNov 2018 · 22 investors · BiotechnologyRule 506(b)
- Stella XuDirector
- Michael RichmanExecutive Officer, Director
- Michael YiDirector
- Judith LiDirector
- Chau Q. KhuongDirector
- Kevin N. HellerExecutive Officer
- David KabakoffDirector
- Steven CobournExecutive Officer
- Tim ShannonDirector
- Elaine JonesDirector
- Offering amount
- $93.4M
- Amount sold
- $93.4M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$15MraisedJan 2016 · 7 investors · BiotechnologyRule 506(b)
- CAROLYN GREENDirector
- ASHER RUBINExecutive Officer
- DAVID KABAKOFFDirector
- TIM SHANNONDirector
- MICHAEL RICHMANExecutive Officer, Director
- JUDITH LIDirector
- CHAU Q. KHUONGDirector
- Offering amount
- $67M
- Amount sold
- $15M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does NextCure do?
- Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
- Who founded NextCure?
- NextCure was founded by Michael Richman in 2015.
- Who are NextCure's investors?
- NextCure's investors include Bay City Capital, Canaan Partners, LAV, Lilly Asia Ventures, Pfizer Venture Investments, Quan Capital, Sofinnova Ventures, Taiho Ventures, LLC and 3 more.
- How much funding has NextCure raised?
- NextCure has disclosed $449.9M raised across 4 rounds.
- Where is NextCure headquartered?
- NextCure is headquartered in Beltsville, US.